Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Top Cited Papers
- 31 December 2012
- journal article
- research article
- Published by Elsevier BV in Ophthalmology
- Vol. 119 (12), 2537-2548
- https://doi.org/10.1016/j.ophtha.2012.09.006
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed DosingOphthalmology, 2011
- Primary Endpoint Results of a Phase II Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-related Macular DegenerationOphthalmology, 2011
- Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE StudyOphthalmology, 2011
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2011
- A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular DegenerationOphthalmology, 2009
- Predicted biological activity of intravitreal VEGF TrapBritish Journal of Ophthalmology, 2008
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1American Journal of Ophthalmology, 2008
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2American Journal of Ophthalmology, 2001